Debiopharm Group, the Swiss-based global biopharmaceutical company that focuses on the development of prescription drugs that target unmet medical needs, including anti-bacterial, oncology and companion diagnostics, and TCG Lifesciences Ltd. (TCGLS) a leading contract research services company in the area of early drug discovery and development, announced that they have reached the first research milestone and consequently enter into lead optimization phase for innovative antibiotics targeting drug-resistant bacteria for community and hospital-acquired infections.
This first step towards identification of new classes of targeted anti-infectious drugs was achieved only nine months after signature of a discovery collaboration will trigger the payment of research milestones by Debiopharm according to a pre-defined research plan.
Dr. Saumitra Sengupta, distinguished scientist at TCG Lifesciences, commented: “The strong collaborative spirit from both sides has resulted in reaching this important milestone. We are excited about partnering with Debiopharm in their search for new antibiotics and wish to continue in the same spirit of value addition in order to bring this project to a meaningful result.”
“This fruitful collaboration with TCG Lifesciences has now delivered early leads ready to enter into the process of lead optimization,” said Andrés McAllister, chief scientific officer, Debiopharm International SA. “It is an important milestone for Debiopharm, supporting our strong commitment to develop novel antibiotics to overcome resistance to current treatments. It is part of our global strategy initiated with the development of our FabI inhibitors, Debio 1450, currently in clinical Phase 1 and Debio 1452 which has already demonstrated high efficacy in the treatment of acute bacterial skin and skin-structure infections in a Phase 2 trial.”
Date: June 24, 2014
Source: Debiopharm Group
Filed Under: Drug Discovery
